Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia
We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 12; číslo 1; s. 12214 - 11 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
16.07.2022
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (
p
< 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points;
p
< 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8;
p
< 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. |
|---|---|
| AbstractList | We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer's disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs- it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:-10.8 vs. -5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:-11.6 vs. -8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53-0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + ( p < 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer's disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs- it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:-10.8 vs. -5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:-11.6 vs. -8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53-0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia.We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer's disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs- it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:-10.8 vs. -5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:-11.6 vs. -8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53-0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. Abstract We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia. |
| ArticleNumber | 12214 |
| Author | Cherubini, Antonio Zuliani, Giovanni Volpato, Stefano Zuin, Marco Ferrucci, Luigi |
| Author_xml | – sequence: 1 givenname: Marco surname: Zuin fullname: Zuin, Marco organization: Department of Translational Medicine, University of Ferrara – sequence: 2 givenname: Antonio surname: Cherubini fullname: Cherubini, Antonio organization: Geriatria, Accettazione Geriatrica e Centro Di Ricerca Per L’invecchiamento, IRCCS INRCA – sequence: 3 givenname: Stefano surname: Volpato fullname: Volpato, Stefano organization: Department of Medical Sciences, University of Ferrara – sequence: 4 givenname: Luigi surname: Ferrucci fullname: Ferrucci, Luigi organization: Translational Gerontology Branch, National Institute On Aging, National Institutes of Health – sequence: 5 givenname: Giovanni surname: Zuliani fullname: Zuliani, Giovanni email: giovanni.zuliani@unife.it organization: Department of Translational Medicine, University of Ferrara |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35842477$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1rGzEQhpeS0qRp_kAPZaGXXrbV51p7KYTQj0Cgl_YsZqVZW0aWXEm28b-PHCdtkkMEQiPpeV9mpHnbnIQYsGneU_KZEq6-ZEHloDrCWEd7Meu73avmjBEhO8YZO3kUnzYXOS9JHZINgg5vmlMulWBiNjtrtpcGy953ZhG9C5gLJsjYubBwoysx5Tb7uGtNnAdX3BZbi-YAthDsIU5Y8TZuq8z7dhVTAe_KvnWhjd5iatdQHIaS250ri6pY1Y2Dd83rCXzGi_v1vPnz_dvvq5_dza8f11eXN52RgpTOCkSrAAyxzMyMBDtKDqMEM5mx55z1ShoA1lMzIyNO1AwwCi4IKKT1nJ8310dfG2Gp18mtIO11BKfvDmKaa0jFGY8aCDBrgUyKUDHZaRj5IJXkpJ8oSNpXr69Hr_VmXKE1tZBa9BPTpzfBLfQ8bvXAlBKKV4NP9wYp_t3Ut9Yrlw16DwHjJmvWD5RIQvuhoh-focu4SaE-1YEivE5JK_XhcUb_Unn43gqoI2BSzDnhpI0r9UPiIUHnNSX60Ez62Ey6NpO-aya9q1L2TPrg_qKIH0W5wmGO6X_aL6huAQDO4PA |
| CitedBy_id | crossref_primary_10_1177_08919887231202948 crossref_primary_10_1007_s13205_025_04295_5 crossref_primary_10_3390_biom13091357 crossref_primary_10_1016_j_psychres_2023_115461 crossref_primary_10_1515_revneuro_2024_0090 crossref_primary_10_1016_j_jocn_2025_111338 crossref_primary_10_1016_j_encep_2025_01_010 crossref_primary_10_1038_s41598_024_54553_4 crossref_primary_10_1186_s40001_025_02886_9 crossref_primary_10_2174_1574885519666230913105725 crossref_primary_10_1016_S0140_6736_24_01296_0 crossref_primary_10_1515_ncrs_2025_0225 crossref_primary_10_3390_molecules29112456 crossref_primary_10_1186_s13065_024_01235_x crossref_primary_10_1177_10600280231218253 crossref_primary_10_1007_s40520_023_02675_6 crossref_primary_10_1186_s12877_023_04627_1 crossref_primary_10_1007_s00044_024_03316_x crossref_primary_10_1177_13872877251330902 crossref_primary_10_1016_j_neuroimage_2025_121092 crossref_primary_10_1016_j_arr_2025_102847 crossref_primary_10_1016_j_brainres_2025_149600 crossref_primary_10_1016_j_archger_2025_105951 crossref_primary_10_3389_fnins_2023_1327886 crossref_primary_10_3389_fphar_2024_1474986 crossref_primary_10_1186_s40001_025_02681_6 crossref_primary_10_1016_j_ejmech_2023_115354 crossref_primary_10_3390_molecules29235711 crossref_primary_10_3390_receptors4010007 crossref_primary_10_1001_jamainternmed_2023_8522 crossref_primary_10_3389_fnagi_2023_1213968 |
| Cites_doi | 10.1002/14651858.CD005593 10.1016/j.jagp.2019.06.008 10.1186/alzrt85 10.1212/wnl.43.2.250 10.1186/s13063-015-1023-4 10.3233/JAD-2009-0926 10.1016/j.archger.2008.07.006 10.1001/archneurol.2011.189 10.1016/S1474-4422(07)70195-3 10.3892/mmr.2019.10374 10.1093/eurheartj/eht182 10.1016/j.neuropharm.2020.108352 10.1080/00273171.2011.568786 10.1007/s41999-019-00265-2 10.1186/s13195-018-0457-9 10.1212/wnl.34.7.939 10.1016/S0140-6736(02)08267-3 10.1093/ageing/afx098 10.1111/j.1532-5415.2010.03032.x 10.1212/WNL.0000000000011832 10.2165/00002512-200421070-00004 10.3233/JAD-181047 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1607::AID-SIM449>3.0.CO;2-O 10.1016/j.trci.2016.12.005 10.1002/gps.1402 10.1093/ijnp/pyv086 10.1016/j.jalz.2012.11.007 10.2165/11310960-000000000-00000 10.1192/bjp.2020.136 10.1159/000486546 10.3233/jad-2006-9s347 10.1007/978-3-319-95387-8_9 10.1186/1471-2296-9-29 10.1002/14651858.CD006504.pub2 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-022-16476-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information Biological Science Database ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_a0a2dda0f8014fdf9b39585306f1a516 PMC9288483 35842477 10_1038_s41598_022_16476_w |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIA/NIH grantid: U01 AG016976; U01 AG016976; U01 AG016976; U01 AG016976 – fundername: NIA NIH HHS grantid: P50 AG047366 – fundername: NIA NIH HHS grantid: P50 AG005131 – fundername: NIA NIH HHS grantid: P30 AG019610 – fundername: NIA NIH HHS grantid: P50 AG005136 – fundername: NIA NIH HHS grantid: P50 AG008702 – fundername: NIA NIH HHS grantid: P50 AG023501 – fundername: NIA NIH HHS grantid: P50 AG047270 – fundername: NIA NIH HHS grantid: P30 AG072947 – fundername: NIA NIH HHS grantid: P50 AG005681 – fundername: NIA NIH HHS grantid: P30 AG008017 – fundername: ; grantid: U01 AG016976; U01 AG016976; U01 AG016976; U01 AG016976 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c540t-d4eed8aac0d2c7c5adb53ab5acfcb6332685caa261c70bef1c9ab4340a8e1aa23 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 35 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000826171200053&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Mon Nov 10 04:33:59 EST 2025 Tue Nov 04 01:47:05 EST 2025 Wed Oct 01 14:21:14 EDT 2025 Tue Oct 07 09:15:05 EDT 2025 Thu Apr 03 07:05:59 EDT 2025 Sat Nov 29 06:26:32 EST 2025 Tue Nov 18 21:55:46 EST 2025 Fri Feb 21 02:36:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-d4eed8aac0d2c7c5adb53ab5acfcb6332685caa261c70bef1c9ab4340a8e1aa23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2690369051?pq-origsite=%requestingapplication% |
| PMID | 35842477 |
| PQID | 2690369051 |
| PQPubID | 2041939 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a0a2dda0f8014fdf9b39585306f1a516 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9288483 proquest_miscellaneous_2691050169 proquest_journals_2690369051 pubmed_primary_35842477 crossref_citationtrail_10_1038_s41598_022_16476_w crossref_primary_10_1038_s41598_022_16476_w springer_journals_10_1038_s41598_022_16476_w |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-16 |
| PublicationDateYYYYMMDD | 2022-07-16 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Mendiondo, Wesson Ashford, Kryscio, Schmitt (CR26) 2000; 19 Ba, Li, Ng, Pascoal, Mathotaarachchi, Rosa-Neto, Gauthier (CR33) 2017; 3 Schmidt, Wolff, Weitz, Bartlau, Korth, Zerr (CR34) 2011; 68 Calabria, Geroldi, Lussignoli, Sabbatini, Zanetti (CR16) 2009; 49 Takeda, Loveman, Clegg, Kirby, Picot, Payne, Green (CR3) 2006; 21 Arvanitakis, Shah, Bennett (CR2) 2019; 322 Mueller, Perera, Hayes, Shetty, Stewart (CR31) 2018; 47 Karen, Tim, Karoline, Oliver, Zuzana (CR29) 2019; 69 Gill (CR19) 2013; 9 Wattmo, Wallin, Londos, Minthon (CR28) 2011; 3 CR38 McKhann, Drachman, Folstein, Katzman, Price, Stadlan (CR35) 1984; 34 CR14 CR36 Tan, Kristina Johnell, Bell, Garcia-Ptacek, Fastbom, Nordström, Eriksdotter (CR32) 2020; 28 Matsunaga, Kishi, Yasue, Iwata (CR24) 2016; 19 Cherubini, Del Signore, Ouslander, Semla, Michel (CR13) 2010; 58 Román, Tatemichi, Erkinjuntti, Cummings, Masdeu, Garcia, Amaducci, Orgogozo, Burn, Hofman (CR37) 1993; 43 Pilon, Poulin, Fortin, Houde, Verret, Bouchard, Laforce (CR20) 2016; 2 Kennedy-Martin, Curtis, Faries, Robinson, Johnston (CR12) 2015; 16 Hong, Garcia-Ptacek, Jönsson, Anders, Nordström, Eriksdotter (CR25) 2021 Sharma (CR11) 2019; 20 Nelson, Kryscio, Abner, Schmitt, Jicha, Mendiondo, Cooper, Smith, Markesbery (CR27) 2009; 16 Austin (CR39) 2011; 46 Marucci, Buccioni, Ben, Lambertucci, Volpini, Amenta (CR4) 2020 Wilkinson, Francis, Schwam, Payne-Parrish (CR5) 2004; 21 Kavirajan, Schneider (CR10) 2007; 6 Birks (CR6) 2006 Erkinjuntti, Kurz, Gauthier, Bullock, Lilienfeld, Damaraju (CR9) 2002; 359 CR23 CR22 CR21 Nordström, Religa, Wimo, Winblad, Eriksdotter (CR30) 2013; 34 Vaci, Koychev, Kim, Kormilitzin, Liu, Lucas, Dehghan, Nenadic, Nevado-Holgado (CR18) 2020 Dou, Tan, Tan, Cao, Hou, Guo, Tan, Mok, Yu (CR8) 2018; 10 Knight, Khondoker, Magill, Stewart, Landau (CR7) 2018; 45 Nelson, Kryscio, Abner, Schmitt, Jicha, Mendiondo, Cooper, Smith, Markesbery (CR15) 2009; 16 Mattiuzzi, Lippi (CR1) 2020; 11 Santoro, Siviero, Minicuci, Bellavista, Mishto, Olivieri, Marchegiani, Chiamenti, Benussi, Ghidoni, Nacmias, Bagnoli, Ginestroni, Scarpino, Feraco, Gianni, Cruciani, Paganelli, Di Iorio, Scognamiglio, Grimaldi, Gabelli, Sorbi, Binetti, Crepaldi, Franceschi (CR17) 2010; 24 J Birks (16476_CR6) 2006 DP Gill (16476_CR19) 2013; 9 PC Austin (16476_CR39) 2011; 46 KX Dou (16476_CR8) 2018; 10 C Wattmo (16476_CR28) 2011; 3 S Matsunaga (16476_CR24) 2016; 19 C Mueller (16476_CR31) 2018; 47 Xu Hong (16476_CR25) 2021 G Marucci (16476_CR4) 2020 R Knight (16476_CR7) 2018; 45 16476_CR21 PT Nelson (16476_CR15) 2009; 16 ECK Tan (16476_CR32) 2020; 28 T Kennedy-Martin (16476_CR12) 2015; 16 MH Pilon (16476_CR20) 2016; 2 PT Nelson (16476_CR27) 2009; 16 16476_CR14 A Santoro (16476_CR17) 2010; 24 16476_CR36 MS Mendiondo (16476_CR26) 2000; 19 16476_CR38 K Sharma (16476_CR11) 2019; 20 C Schmidt (16476_CR34) 2011; 68 A Cherubini (16476_CR13) 2010; 58 G McKhann (16476_CR35) 1984; 34 A Takeda (16476_CR3) 2006; 21 M Ba (16476_CR33) 2017; 3 H Kavirajan (16476_CR10) 2007; 6 N Vaci (16476_CR18) 2020 16476_CR22 S Karen (16476_CR29) 2019; 69 Z Arvanitakis (16476_CR2) 2019; 322 16476_CR23 T Erkinjuntti (16476_CR9) 2002; 359 M Calabria (16476_CR16) 2009; 49 C Mattiuzzi (16476_CR1) 2020; 11 P Nordström (16476_CR30) 2013; 34 DG Wilkinson (16476_CR5) 2004; 21 GC Román (16476_CR37) 1993; 43 |
| References_xml | – ident: CR22 – year: 2006 ident: CR6 article-title: Cholinesterase inhibitors for Alzheimer's disease publication-title: Cochrane Database Syst. Rev. doi: 10.1002/14651858.CD005593 – volume: 28 start-page: 108 issue: 1 year: 2020 end-page: 117 ident: CR32 article-title: Do Acetylcholinesterase inhibitors prevent or delay psychotropic prescribing in people with dementia? Analyses of the Swedish dementia registry publication-title: Am. J. Geriatric Psychiatry doi: 10.1016/j.jagp.2019.06.008 – volume: 3 start-page: 23 year: 2011 ident: CR28 article-title: Predictors of long-term cognitive outcome in Alzheimer’s disease publication-title: Alzheimer’s Res. Ther. doi: 10.1186/alzrt85 – volume: 43 start-page: 250 year: 1993 end-page: 260 ident: CR37 article-title: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop publication-title: Neurology doi: 10.1212/wnl.43.2.250 – ident: CR14 – volume: 16 start-page: 495 year: 2015 ident: CR12 article-title: A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results publication-title: Trials doi: 10.1186/s13063-015-1023-4 – volume: 16 start-page: 29 year: 2009 end-page: 34 ident: CR15 article-title: Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB publication-title: J. Alzheimers Dis. doi: 10.3233/JAD-2009-0926 – volume: 49 start-page: e6 year: 2009 end-page: e11 ident: CR16 article-title: Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer’s disease: A 21-month follow-up ‘‘real world’’ study publication-title: Arch. Gerontol. Geriatr. doi: 10.1016/j.archger.2008.07.006 – volume: 68 start-page: 1124 year: 2011 end-page: 1130 ident: CR34 article-title: Rapidly progressive Alzheimer disease publication-title: Arch. Neurol. doi: 10.1001/archneurol.2011.189 – volume: 6 start-page: 782 year: 2007 end-page: 792 ident: CR10 article-title: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(07)70195-3 – volume: 20 start-page: 1479 year: 2019 end-page: 1487 ident: CR11 article-title: Cholinesterase inhibitors as Alzheimer's therapeutics (Review) publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2019.10374 – volume: 34 start-page: 2585 year: 2013 end-page: 2591 ident: CR30 article-title: The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease publication-title: Eur. Heart J. doi: 10.1093/eurheartj/eht182 – year: 2020 ident: CR4 article-title: Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2020.108352 – ident: CR23 – volume: 46 start-page: 399 year: 2011 end-page: 424 ident: CR39 article-title: An introduction to propensity score methods for reducing the effects of confounding in observational studies publication-title: Multivar. Behav. Res. doi: 10.1080/00273171.2011.568786 – volume: 11 start-page: 147 year: 2020 end-page: 153 ident: CR1 article-title: Worldwide disease epidemiology in the older persons publication-title: Eur. Geriatr. Med. doi: 10.1007/s41999-019-00265-2 – ident: CR21 – volume: 10 start-page: 126 year: 2018 ident: CR8 article-title: Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: A network meta-analysis of 41 randomized controlled trials publication-title: Alzheimers Res. Ther. doi: 10.1186/s13195-018-0457-9 – volume: 34 start-page: 939 year: 1984 end-page: 944 ident: CR35 article-title: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease publication-title: Neurology doi: 10.1212/wnl.34.7.939 – volume: 359 start-page: 1283 year: 2002 end-page: 1290 ident: CR9 article-title: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08267-3 – ident: CR38 – volume: 47 start-page: 88 year: 2018 end-page: 94 ident: CR31 article-title: Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: A retrospective survival analysis publication-title: Age Ageing. doi: 10.1093/ageing/afx098 – volume: 58 start-page: 1791 year: 2010 end-page: 1796 ident: CR13 article-title: Fighting against age discrimination in clinical trials publication-title: J. Am. Geriatr. Soc. doi: 10.1111/j.1532-5415.2010.03032.x – year: 2021 ident: CR25 article-title: Long term effects of cholinesterase inhibitors on cognitive decline and mortality publication-title: Neurology doi: 10.1212/WNL.0000000000011832 – volume: 322 start-page: 15891599 year: 2019 ident: CR2 article-title: Diagnosit and management of dementia: Review publication-title: JAMA – volume: 21 start-page: 453 year: 2004 end-page: 478 ident: CR5 article-title: Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy publication-title: Drugs Aging. doi: 10.2165/00002512-200421070-00004 – volume: 69 start-page: 1153 issue: 4 year: 2019 end-page: 1160 ident: CR29 article-title: Rate of cognitive decline in alzheimer’s disease stratified by age publication-title: J. Alzheimers Dis. doi: 10.3233/JAD-181047 – volume: 19 start-page: 1607 year: 2000 end-page: 1616 ident: CR26 article-title: Modelling mini mental state examination changes in alzheimer's disease publication-title: Statist. Med. doi: 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1607::AID-SIM449>3.0.CO;2-O – volume: 3 start-page: 107 year: 2017 end-page: 113 ident: CR33 article-title: Alzheimer's disease neuroimaging initiative. The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database publication-title: Alzheimers Dement. (N Y) doi: 10.1016/j.trci.2016.12.005 – volume: 21 start-page: 17 year: 2006 end-page: 28 ident: CR3 article-title: A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease publication-title: Int. J. Geriatr. Psychiatry. doi: 10.1002/gps.1402 – ident: CR36 – volume: 19 start-page: pyv086 year: 2016 ident: CR24 article-title: Cholinesterase inhibitors for lewy body disorders: A meta-analysis publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyv086 – volume: 9 start-page: S63 year: 2013 end-page: S71 ident: CR19 article-title: Differences in rate of functional decline across three dementia types publication-title: Alzheimer’s Dementia. doi: 10.1016/j.jalz.2012.11.007 – volume: 2 start-page: 278 year: 2016 end-page: 286 ident: CR20 article-title: Differences in rate of cognitive decline and caregiver burden between alzheimer's disease and vascular dementia: A retrospective study publication-title: Neurology (ECronicon). – volume: 24 start-page: 163 year: 2010 end-page: 176 ident: CR17 article-title: Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: A prospective, observational study publication-title: CNS Drugs doi: 10.2165/11310960-000000000-00000 – year: 2020 ident: CR18 article-title: Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: Retrospective health record study publication-title: Br. J. Psychiatry doi: 10.1192/bjp.2020.136 – volume: 16 start-page: 29 issue: 1 year: 2009 end-page: 34 ident: CR27 article-title: Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with alzheimer's disease and AD + DLB publication-title: J Alzheimers Dis. doi: 10.3233/JAD-2009-0926 – volume: 45 start-page: 131 year: 2018 end-page: 151 ident: CR7 article-title: A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia publication-title: Dement. Geriatr. Cogn. Disord. doi: 10.1159/000486546 – volume: 21 start-page: 453 year: 2004 ident: 16476_CR5 publication-title: Drugs Aging. doi: 10.2165/00002512-200421070-00004 – volume: 34 start-page: 939 year: 1984 ident: 16476_CR35 publication-title: Neurology doi: 10.1212/wnl.34.7.939 – volume: 43 start-page: 250 year: 1993 ident: 16476_CR37 publication-title: Neurology doi: 10.1212/wnl.43.2.250 – ident: 16476_CR22 – volume: 34 start-page: 2585 year: 2013 ident: 16476_CR30 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/eht182 – volume: 20 start-page: 1479 year: 2019 ident: 16476_CR11 publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2019.10374 – ident: 16476_CR36 doi: 10.3233/jad-2006-9s347 – volume: 21 start-page: 17 year: 2006 ident: 16476_CR3 publication-title: Int. J. Geriatr. Psychiatry. doi: 10.1002/gps.1402 – year: 2006 ident: 16476_CR6 publication-title: Cochrane Database Syst. Rev. doi: 10.1002/14651858.CD005593 – volume: 322 start-page: 15891599 year: 2019 ident: 16476_CR2 publication-title: JAMA – volume: 9 start-page: S63 year: 2013 ident: 16476_CR19 publication-title: Alzheimer’s Dementia. doi: 10.1016/j.jalz.2012.11.007 – ident: 16476_CR14 doi: 10.1007/978-3-319-95387-8_9 – volume: 46 start-page: 399 year: 2011 ident: 16476_CR39 publication-title: Multivar. Behav. Res. doi: 10.1080/00273171.2011.568786 – volume: 359 start-page: 1283 year: 2002 ident: 16476_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(02)08267-3 – volume: 24 start-page: 163 year: 2010 ident: 16476_CR17 publication-title: CNS Drugs doi: 10.2165/11310960-000000000-00000 – volume: 6 start-page: 782 year: 2007 ident: 16476_CR10 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(07)70195-3 – year: 2020 ident: 16476_CR18 publication-title: Br. J. Psychiatry doi: 10.1192/bjp.2020.136 – year: 2021 ident: 16476_CR25 publication-title: Neurology doi: 10.1212/WNL.0000000000011832 – ident: 16476_CR38 doi: 10.1186/1471-2296-9-29 – volume: 3 start-page: 23 year: 2011 ident: 16476_CR28 publication-title: Alzheimer’s Res. Ther. doi: 10.1186/alzrt85 – volume: 58 start-page: 1791 year: 2010 ident: 16476_CR13 publication-title: J. Am. Geriatr. Soc. doi: 10.1111/j.1532-5415.2010.03032.x – volume: 45 start-page: 131 year: 2018 ident: 16476_CR7 publication-title: Dement. Geriatr. Cogn. Disord. doi: 10.1159/000486546 – year: 2020 ident: 16476_CR4 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2020.108352 – volume: 2 start-page: 278 year: 2016 ident: 16476_CR20 publication-title: Neurology (ECronicon). – ident: 16476_CR21 – volume: 47 start-page: 88 year: 2018 ident: 16476_CR31 publication-title: Age Ageing. doi: 10.1093/ageing/afx098 – volume: 28 start-page: 108 issue: 1 year: 2020 ident: 16476_CR32 publication-title: Am. J. Geriatric Psychiatry doi: 10.1016/j.jagp.2019.06.008 – ident: 16476_CR23 doi: 10.1002/14651858.CD006504.pub2 – volume: 49 start-page: e6 year: 2009 ident: 16476_CR16 publication-title: Arch. Gerontol. Geriatr. doi: 10.1016/j.archger.2008.07.006 – volume: 19 start-page: pyv086 year: 2016 ident: 16476_CR24 publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyv086 – volume: 69 start-page: 1153 issue: 4 year: 2019 ident: 16476_CR29 publication-title: J. Alzheimers Dis. doi: 10.3233/JAD-181047 – volume: 11 start-page: 147 year: 2020 ident: 16476_CR1 publication-title: Eur. Geriatr. Med. doi: 10.1007/s41999-019-00265-2 – volume: 10 start-page: 126 year: 2018 ident: 16476_CR8 publication-title: Alzheimers Res. Ther. doi: 10.1186/s13195-018-0457-9 – volume: 16 start-page: 495 year: 2015 ident: 16476_CR12 publication-title: Trials doi: 10.1186/s13063-015-1023-4 – volume: 3 start-page: 107 year: 2017 ident: 16476_CR33 publication-title: Alzheimers Dement. (N Y) doi: 10.1016/j.trci.2016.12.005 – volume: 68 start-page: 1124 year: 2011 ident: 16476_CR34 publication-title: Arch. Neurol. doi: 10.1001/archneurol.2011.189 – volume: 16 start-page: 29 year: 2009 ident: 16476_CR15 publication-title: J. Alzheimers Dis. doi: 10.3233/JAD-2009-0926 – volume: 16 start-page: 29 issue: 1 year: 2009 ident: 16476_CR27 publication-title: J Alzheimers Dis. doi: 10.3233/JAD-2009-0926 – volume: 19 start-page: 1607 year: 2000 ident: 16476_CR26 publication-title: Statist. Med. doi: 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1607::AID-SIM449>3.0.CO;2-O |
| SSID | ssj0000529419 |
| Score | 2.5251122 |
| Snippet | We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late... Abstract We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 12214 |
| SubjectTerms | 631/378/2612 692/308/174 692/308/409 692/617/375 Aged Alzheimer Disease - psychology Alzheimer's disease Cholinesterase Cholinesterase Inhibitors - therapeutic use Cholinesterases Cognitive ability Cognitive Dysfunction - chemically induced Cognitive Dysfunction - drug therapy Dementia Dementia disorders Humanities and Social Sciences Humans Lewy bodies Lewy Body Disease Mortality multidisciplinary Neurodegenerative diseases Older people Patients Regression analysis Science Science (multidisciplinary) Sexually transmitted diseases STD Vascular dementia |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hCiQuiDehBRmJG0RN7DzsY0FUnCoOIPVmTRxbjRSyqNl21X_fGSebdnleuEV-KNbMOPM5nvkG4K0PiDJD0kCBGV8zNqlWBR1cjfdO18j8JLHYRH1yok9PzZdbpb44JmyiB54Ed4gZyrbFLDDNSWiDaZQhiEtIN-RY5pFsm1DPrcPUxOotDb14zpLJlD4cyVNxNhmdvZhCq0o3O54oEvb_DmX-Giz5041pdETHD-HBjCDF0bTyR3DHD4_h3lRT8uoJXB45v77qU_6scUg7ZxiPPu2Gs67puLSOGPvVRixhQ6L1nB3pBQ4tP3OQuhcc2Il9L75HdE5IXXSDWHFFbzEzsY6Cf-HSjBhvhE_h2_Gnrx8_p3NxhdQRSFunbUHeUSO6rJWudiW2TamwKdEF11SKUJ0uHemxyl2dNT7kzmBTqIL06nNqV89gb1gN_gWI0hWc7FMopwP1owm-DN41UhqPVRUSyLeCtm5mHucCGL2NN-BK20k5lpRjo3LsJoF3y5wfE-_GX0d_YP0tI5kzOzaQJdnZkuy_LCmBg6327byRRysrQz6eScwSeLN00xbkexUc_OoijiGUyrQ2CTyfjGVZiSKAJ4u6TqDeMaOdpe72DN1ZpPk2UutCqwTebw3uZll_FsXL_yGKfbgveacwgWh1AHvr8wv_Cu66y3U3nr-OW-0aA4owVg priority: 102 providerName: Directory of Open Access Journals |
| Title | Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia |
| URI | https://link.springer.com/article/10.1038/s41598-022-16476-w https://www.ncbi.nlm.nih.gov/pubmed/35842477 https://www.proquest.com/docview/2690369051 https://www.proquest.com/docview/2691050169 https://pubmed.ncbi.nlm.nih.gov/PMC9288483 https://doaj.org/article/a0a2dda0f8014fdf9b39585306f1a516 |
| Volume | 12 |
| WOSCitedRecordID | wos000826171200053&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Biological Science Database (NC LIVE) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection (NC LIVE) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Science Database (NC LIVE) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RXZC48H4EyspI3CBqEufhnFCLWsGhqxUCaTlFjmPTSCEpm21X_ffMON5Uy6MXLlYUO5KdGdvz_AbgjTZSRoFECsQyIDdj6Qseo-Kaa61EJgmfxBabyOZzsVzmC2dw611Y5fZMtAd11SmykR9EqMbxlNCk3p__9KlqFHlXXQmNPZgSUlk8genR8XzxebSykB8LJ-CyZQIuDnq8sSirDHUwgtJK_c3OjWSB-_8mbf4ZNPmb59ReSCf3_3cpD-CeE0XZ4cA7D-GWbh_BnaE45dVjuDxUen3V-HQ-Umw8pSr32q_bs7qsqUYP65tuw8b4I1ZpSrPUTLYVPVO0u2YUISqbhv2wYj6K_KxuWUelwZmDdO0Z2YLxCxu4JJ_A15PjLx8--q5Kg69Q2lv7VYzXrJBSBVWkMpXIqky4LBOpjCpTjuKhSBQyRBqqLCi1CVUuy5jHyCA6xPf8KUzartXPgSUqpqyhmCthsF_mRidGqzKKci3T1HgQbilVKAdhTpU0msK60rkoBuoWSN3CUrfYePB2_OZ8APC4cfQRMcA4ksC37Ytu9b1we7mQgYyqSgaGkHdMZfKS56h1ofJlQpmEqQf7W7oX7kToi2uie_B67Ma9TA4a2eruwo5BcZfwcTx4NnDbOBOOkmIUZ5kH2Q4f7kx1t6etzyxeeB4JEQvuwbstx15P69-_4sXNq3gJdyPaRIQxmu7DZL260K_gtrpc1_1qBnvZMrOtmLk9ObPmDmxPowW1GbbTxafTxbdfwAFGFg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoIL70eggJHgBFETOw_ngFB5VK1aVhyK1JtxHIdGWpKy2Xa1f4rfyIzzqJZHbz1wi2In8iSfxzP2zDcAL2ypNQ80_oFIB3TMmPtSROi4ZtYamWriJ3HFJtLJRB4eZp_X4OeQC0NhlYNOdIq6aAztkW9ydONEQmxSb49_-FQ1ik5XhxIaHSz27HKBLlv7ZvcD_t-XnG9_PHi_4_dVBXyD1sncLyJcFqTWJii4SU2sizwWOo-1KU2eCDRnZGxQgCQ0aZDbMjSZziMRoUA2xPsC33sJLqMeTymELD1Mxz0dOjVDcfvcnEDIzRbXR8phQ4-PiLsSf7Gy_rkyAX-zbf8M0fztnNYtf9s3_7cPdwtu9IY22-pmxm1Ys_UduNqV3lzehdMtY-fLqU_anyL_KRG7tX5VH1V5RRWIWDttFmyMrmKFpSRSy3Rd0DXF8ltG8a96OmXfnRODDg2ratZQ4XPWE9a2jHa68QkXlqXvwZcLEfo-rNdNbR8Ci01EOVGRMLLEdp2VNi6tyTnPrE6S0oNwQIYyPUE71QmZKhcoIKTq0KQQTcqhSS08eDU-c9zRk5zb-x0BbuxJ1OLuRjP7pnpNpXSgeVHooCReobIos1xk6FOia1mGOg4TDzYGnKle37XqDGQePB-bUVPR8ZOubXPi-qAxT-w_Hjzo0D2ORKAdzKM09SBdwf3KUFdb6urIsaFnXMpICg9eDzPkbFj__hSPzpfiGVzbOfi0r_Z3J3uP4TqnCUxsqskGrM9nJ_YJXDGn86qdPXUagMHXi545vwCWUKAC |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAhUX3o9AASPBCaJN7DwPCBXKiqqw2gNIvaWOY9NI26Rstl3tX-PXMeM8quXRWw_cotiJPMnMeMYz8w3AS22k5J7EPxBIj8KMuZuIAB3XVGuVxJLwSWyziXgySQ4O0ukG_OxrYSitsteJVlEXtaIz8hFHN05EhCY1Ml1axHR3_O7kh0sdpCjS2rfTaFlkX6-W6L41b_d28V-_4nz88euHT27XYcBVaKks3CLALSKRUnkFV7EKZZGHQuahVEblkUDTJgkVEhP5KvZybXyVyjwQARKnfbwv8L1X4GochCFJ1xc-Hc53KIKGpHd1Op5IRg3ulVTPht4fgXhF7nJtL7QtA_5m5_6ZrvlbzNZuheNb__NHvA03OwOc7bQScwc2dHUXrrctOVf34GxH6cVq5tKuQBUBVKDdaLesjsq8pM5ErJnVSzZkXbFCU3GpZrIq6Jpy_DWjvFg5m7Fj69ygo8PKitXUEJ11QLYNoxNwfMKma8n78O1SiH4Am1Vd6UfAQhVQrVQgVGJwXKZGh0arnPNUyygyDvg9l2SqA26n_iGzzCYQiCRrOStDzsosZ2VLB14Pz5y0sCUXzn5PzDfMJMhxe6Oef886DZZJT_KikJ4hvCFTmDQXKfqa6HIaX4Z-5MB2z3NZpweb7JzhHHgxDKMGo7CUrHR9auegkU-oQA48bDl9WIlA-5gHcexAvCYDa0tdH6nKI4uSnvIkCRLhwJteWs6X9e9P8fhiKp7DFgpM9nlvsv8EbnCSZQJZjbZhczE_1U_hmjpblM38mVUGDA4vW3B-AcmXqM8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acetyl-cholinesterase-inhibitors+slow+cognitive+decline+and+decrease+overall+mortality+in+older+patients+with+dementia&rft.jtitle=Scientific+reports&rft.au=Zuin%2C+Marco&rft.au=Cherubini%2C+Antonio&rft.au=Volpato%2C+Stefano&rft.au=Ferrucci%2C+Luigi&rft.date=2022-07-16&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-16476-w&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |